Т.А. Аbdullayev, О.Kh. Аllaberganov, B.U. Mardanov, R.Sh. Bekbulatova Clinical and hemodynamic effects of trimetazidine in patients with hypertrophic cardiomyopathy.

The aim of investigation was to study efficiency of trimetazidine in patients with hypertrophic cardiomyopathy (HCMP). The study included 38 patients with HCMP (38.4±2.9 years), 74% – males. The investigations included 12-lead ECG, echocardiography, Holter ECG monitoring, exercise test, subjective evaluation of the anginal pain. The patients from the first group (n=20) received trimetazidine 70 mg daily in addition to carvedilol, second group (n=18) – only traditional treatment. The follow-up duration was 3 months. More that half of patients had angina symptoms. Combined treatment with carvedilol and trimetazidine decreased angina and improved exercise tolerance.

Full article